Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Safety of maintenance bevacizumab after first-line chemotherapy for advanced ovarian and müllerian cancers

Safety of maintenance bevacizumab after first-line chemotherapy for advanced ovarian and müllerian cancers. Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings Part I. 2007; Vol 25, No. 18S (June 20 Suppl(abstract 5517).


Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.